Research On Financial Risk Evaluation Of Pharmaceutical Enterprises Under The Background Of Quantity Procurement

In the era of rapidly changing economic situation,the market environment of enterprises is more complex and changeable,and financial risks are threatening the normal operation and development of enterprises.It is of great significance for enterprises to evaluate the financial risks reasonably and accurately and put forward preventive control measures.The pharmaceutical industry is closely related to people's healthy life.The price and curative effect of drugs not only affect the operation and development of enterprises,but also affect the medical treatment of the majority of people.For a long time,China's pharmaceutical industry has been faced with the situation of expensive imported original drugs,small scale,scattered distribution and uneven product quality of local generic drug enterprises,and the cost of medical treatment has been high.The formal implementation of "4+7" bulk procurement not only reduces the drug price and solves the problem of low efficiency and high cost for the majority of people to see a doctor,but also promotes the formation of a new pattern of Chinese pharmaceutical enterprises.Drug consistency evaluation has become a necessary condition for participating in bulk procurement,which is both an opportunity and a challenge for pharmaceutical enterprises,especially generic pharmaceutical enterprises.The bring the implementation of the procurement policy makes the bidding drug prices fell sharply,while effectively reduce people's medical treatment cost compressed pharmaceutical enterprise especially generics companies profit space,prompting companies to more money into in order to gain more profits of the original drug research and development,successfully accelerate the development speed,and integration of industry,the pharmaceutical industry.It has become an important problem for pharmaceutical enterprises to understand the impact of bulk procurement on themselves and determine the change of financial risk level after the implementation of the policy.As one of the "4+7" procurement enterprises,Dezhan Healthcare won the bidding of the drug Atorvastatin Calcium Tablets,the main product of the enterprise,accounting for more than 95% of the operating income,has a strong representative.Dezhan Healthcare is used as the research object in this parper,according to the features of the pharmaceutical industry and bring procurement policy under the current situation of drug prices sharply lower,combining with the preliminary identification of the Dezhan Healthcare financial risk,selected 14 financial indicators,were used to evaluate the enterprise financing risk,investment risk andoperational risk level,established the evaluation index system of financial risk.According to the index system,data were obtained and screened from Dezhan Healthcare's financial statements and the WIND database,and the data after it officially entered the pharmaceutical industry was decided to be the analysis object,and the data interval was subdivided into quarters,in order to accurately identify the financial risk level before and after the enterprise won the bid for the purchase of large quantities.Elected after the required data,try to use Excel software to form the original data matrix,and use the entropy weight method to standardization of original data,to facilitate further concluded that entropy and entropy weight of each index in the financial risk evaluation system weight for each indicator,score,then financial risk evaluation model is set up based on topsis method,calculates the ideal solution and negative ideal solution of each index,the Euclidean distance and relative degree of evaluation object parameters,and according to the relative degree of each evaluation objects to sort,exhibit to determine Dezhan Healthcare's each quarter financial risk condition.According to the evaluation results,the bulk purchase has a certain positive impact on the health financing risk of the German exhibition,and a greater negative impact on the investment risk and operation risk,and the overall financial risk of the enterprise increases.Further analyzes the evaluation results,found that profit as ever higher levels of generics firms,Dezhan Healthcare has accumulated enough for the debts of the enterprise all of its own funds,risk increase rate was not enough to make the enterprise in crisis,but generics margins sharply compression to make enterprises have to seek new ways to bring the purchasing policy of main effect has been reflected.Finally,according to the financial risk assessment and analysis results,the corresponding control measures are proposed,in order to provide reference experience for similar pharmaceutical enterprises to prevent and control financial risks.